Investigating how leukemia stem cells survive and resist treatment
Official title: Diversity Supplement for R37 Grant
Funded at Ut Southwestern Medical Center · NIH-11064631 · Data updated 2026-11-12
This study is looking at how certain leukemia stem cells survive and resist treatment in acute myeloid leukemia, with the hope of finding new ways to target and eliminate these cells to help improve outcomes for patients like you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $67,237 |
| NIH project number | 3R37CA273232-02S1 |
| Project ID | NIH-11064631 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with high-risk genetic subtypes.
✕Less likely to help
Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms that allow leukemia stem cells (LSCs) to survive and resist treatment in acute myeloid leukemia (AML). The project involves ribosome profiling to identify key regulators of LSCs that are selectively translated during protein synthesis. By examining specific genetic subtypes of AML, the research aims to determine how these LSCs depend on regulated protein synthesis for their self-renewal. Ultimately, the goal is to develop new therapies that can effectively target and eliminate LSCs, improving treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target and eradicate leukemia stem cells, improving survival rates for AML patients.
How similar studies have gone: Previous research has shown promise in targeting leukemia stem cells, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Chung, Stephen Shiu-Wah — Ut Southwestern Medical Center
- Study coordinator: Chung, Stephen Shiu-Wah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.